Welcome to PsychU!

Considerations For Patients Receiving Long-Acting Injectable Antipsychotics During COVID-19

In this presentation, René Kahn, MD, PhD, PsychU Schizophrenia Section Advisor, discusses the impact of COVID-19 on long-acting injectable (LAI) antipsychotic administration, including safety and clinical considerations. Dr. Kahn will also discuss the personal protective equipment (PPE) recommendations from the Substance Abuse and Mental Health Services Administration (SAMHSA).

Download Resource

René Kahn, MD, PhD, is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.Jehan Marino, PharmD, BCPP, is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Join PsychU today at no cost for access to this and other premium content!

Join today for instant access to all PsychU content, events, and more!

Membership is free!